We are live on ! Find out more
VINC

Vincerx Pharma, Inc. Common Stock
VINC

Delisted

VINC was delisted on the 22nd of April, 2025.

Back to rankings

36 hedge funds and large institutions have $13.3M invested in Vincerx Pharma, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

17% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 6

3% more funds holding

Funds holding: 35 → 36 (+1)

2% more capital invested

Capital invested by funds: $13M → $13.3M (+$315K)

Holders
36
Holders Change
+1
Holders Change %
+2.86%
% of All Funds
0.57%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
7
Reduced
6
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ECM
ExodusPoint Capital Management
New York
+$158K
2
SSA
Schonfeld Strategic Advisors
New York
+$64.6K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$30.4K
4
Millennium Management
Millennium Management
New York
+$16.9K
5
Renaissance Technologies
Renaissance Technologies
New York
+$15.7K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$164K
2
BlackRock
BlackRock
New York
-$27.1K
3
TC
Tejara Capital
United Kingdom
-$22.4K
4
RC
RBF Capital
California
-$11K
5
Goldman Sachs
Goldman Sachs
New York
-$10.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
1
Goldman Sachs
New York
$2.15M -$10.5K -469 -0.5%
SRC
2
Sage Rhino Capital
California
$1.75M – – –
AAA
3
Affinity Asset Advisors
New York
$1.55M – – –
LFCM
4
Long Focus Capital Management
Puerto Rico
$1.47M – – –
RSCM
5
Rock Springs Capital Management
Maryland
$927K – – –
SSA
6
Schonfeld Strategic Advisors
New York
$656K +$64.6K +2,884 +10%
Citadel Advisors
7
Citadel Advisors
Florida
$649K – – –
Vanguard Group
8
Vanguard Group
Pennsylvania
$541K – – –
ECM
9
ExodusPoint Capital Management
New York
$407K +$158K +7,037 +56%
RCMNY
10
Rubric Capital Management (New York)
New York
$402K – – –
KCM
11
Kingdon Capital Management
New York
$400K – – –
SM
12
Sabby Management
Florida
$368K -$164K -7,330 -29%
Point72 Asset Management
13
Point72 Asset Management
Connecticut
$359K +$560 +25 +0.1%
TC
14
Tejara Capital
United Kingdom
$303K -$22.4K -1,000 -6%
BBA
15
Baker Bros. Advisors
New York
$251K – – –
Renaissance Technologies
16
Renaissance Technologies
New York
$203K +$15.7K +700 +8%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$142K – – –
BlackRock
18
BlackRock
New York
$119K -$27.1K -1,209 -17%
SCM
19
Sio Capital Management
New York
$106K – – –
TCM
20
Tang Capital Management
California
$106K – – –
CC
21
Clearline Capital
New York
$103K – – –
Millennium Management
22
Millennium Management
New York
$89K +$16.9K +755 +22%
LP
23
LMR Partners
United Kingdom
$62.4K – – –
State Street
24
State Street
Massachusetts
$44.9K – – –
Acadian Asset Management
25
Acadian Asset Management
Massachusetts
$42K – – –
1
2

VINC Hedge Fund Activity: Q1 2023 in Review

36 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Vincerx Pharma, Inc. Common Stock (VINC) for Q1 2023, worth a combined $13.3M — up 2.4% from $13M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new VINC positions and 1 closed out — a net gain of 1 holder — while 7 added to existing stakes and 6 trimmed.

The largest buyer was ExodusPoint Capital Management, adding an estimated $158K. The largest seller was Sabby Management, cutting an estimated $164K.

  • 36 institutional investors held Vincerx Pharma, Inc. Common Stock (VINC) as of Q1 2023, up from 35 in Q4 2022.
  • Funds reported $13.3M of Vincerx Pharma, Inc. Common Stock stock for Q1 2023, up 2.4% quarter-over-quarter.
  • 2 funds opened new Vincerx Pharma, Inc. Common Stock positions in Q1 2023 and 1 closed out, a net change of +1 holder.
  • The largest Vincerx Pharma, Inc. Common Stock buyer in Q1 2023 was ExodusPoint Capital Management, an estimated $158K added.
  • The largest Vincerx Pharma, Inc. Common Stock seller in Q1 2023 was Sabby Management, an estimated $164K sold.

Based on aggregated 13F filings for Q1 2023.